Review Opinion of the Compensation and Assessment Committee on the Company's 2026 Restricted Stock Incentive Plan
Weining Health Technology Group Co., Ltd. (hereinafter referred to as "the Company") Compensation and Assessment Committee of the Board of Directors has conducted a review of the Company's "2026 Restricted Stock Incentive Plan (Draft)" (hereinafter referred to as "the Incentive Plan (Draft)" or "this Incentive Plan") and related matters in accordance with the "Company Law of the People's Republic of China" (hereinafter referred to as "the Company Law"), "Securities Law of the People's Republic of China" (hereinafter referred to as "the Securities Law"), "Administrative Measures for Equity Incentives of Listed Companies" (hereinafter referred to as "the Management Measures"), "Listing Rules of the Shenzhen Stock Exchange for Growth Enterprises" (hereinafter referred to as "the Listing Rules"), "Self-Regulatory Guidelines No. 1 for Growth Enterprise Market Listed Companies" (hereinafter referred to as "the Self-Regulatory Guidelines"), and the relevant provisions of the "Articles of Association of Weining Health Technology Group Co., Ltd." (hereinafter referred to as "the Articles of Association"). The review opinions are as follows: